Longeveron's Lomecel-B™ improved cognitive function and brain volume in mild Alzheimer's patients in a Phase 2a trial.

Longeveron Inc., a regenerative medicine biotech firm, presented positive Phase 2a trial results for Lomecel-B™ at the Alzheimer's Association International Conference. The CLEAR MIND study showed Lomecel-B™ improved cognitive function, quality of life, and brain volume in 48 patients with mild Alzheimer's. The therapy met safety, target engagement, and efficacy objectives, with no serious adverse reactions.